How Lipitor Lowers Cholesterol
Lipitor (atorvastatin) mainly regulates HMG-CoA reductase, the enzyme that limits the rate of cholesterol synthesis in the liver. By competitively inhibiting this protein, Lipitor reduces the liver's production of cholesterol, prompting increased uptake of LDL cholesterol from the blood via LDL receptors.[1]
What Happens in the Cholesterol Pathway
HMG-CoA reductase converts HMG-CoA to mevalonate, the first committed step in the mevalonate pathway leading to cholesterol. Blocking it cuts cholesterol output by up to 50% at typical doses, also lowering triglycerides and raising HDL slightly.1
Why This Protein Matters for Patients
Most cholesterol (about 80%) comes from liver synthesis, not diet, so targeting HMG-CoA reductase addresses the primary source. Statins like Lipitor cut cardiovascular risk by 20-30% in high-risk patients by dropping LDL levels 30-60%.2
How It Compares to Other Statins
All statins (e.g., simvastatin, rosuvastatin) hit HMG-CoA reductase but vary in potency and liver selectivity. Lipitor binds tightly with a long half-life, allowing once-daily dosing.[1]
Common Patient Concerns with This Mechanism
Inhibition reduces mevalonate for other molecules like coenzyme Q10, potentially causing muscle pain (5-10% of users) or rare rhabdomyolysis. Liver enzyme monitoring is standard.2
[1]: https://www.drugpatentwatch.com/p/tradename/LIPITOR